{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-008919","form_type":"8-K","ticker":"ETON","cik":"0001710340","company_name":"Eton Pharmaceuticals, Inc.","filed_at":"2024-03-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.203755+00:00","generated_at":"2026-06-04T09:07:13.755812+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Eton Pharma acquires U.S. rights to PKU GOLIKE for $2.2M upfront plus milestones and 30% royalty","bullets":["Acquired U.S. rights to PKU GOLIKE for $2.2M upfront, up to $2M milestones, and 30% royalty on net sales.","PKU GOLIKE targets phenylketonuria (PKU) in an estimated $100M U.S. medical formula market.","Deal expected to be accretive to 2024 earnings; peak sales forecast >$10M annually.","Also acquired U.S. rights to line extensions for tyrosinemia, homocystinuria (launch 2025/2026) and right of first negotiation for RLF-OD032.","Product complements Eton's metabolic franchise; promoted by existing sales force targeting metabolic geneticists."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-008919","json":"https://secwatch.observer/filing/0001437749-24-008919.json","markdown":"https://secwatch.observer/filing/0001437749-24-008919.md","text":"https://secwatch.observer/filing/0001437749-24-008919.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924008919/0001437749-24-008919-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710340/000143774924008919/eton20240318_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T09:07:13.755812+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}